Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond

類似資料

• 1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond
  著者:: Joshi, K., 等
  出版事項: (2020)
• 180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19
  著者:: Cui, W., 等
  出版事項: (2021)
• A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma
  著者:: Minchom, Anna, 等
  出版事項: (2019)
• Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience
  著者:: Cui, Wanyuan, 等
  出版事項: (2020)
• The diagnosis and treatment of brain metastases in EGFR mutant lung cancer
  著者:: Minchom, Anna, 等
  出版事項: (2014)